EGM
PTGX icon

Engineers Gate Manager’s Protagonist Therapeutics PTGX Stock Holding History

Engineers Gate Manager’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,327
Closed -$741K – 2471
2025
Q1 		$741K Buy
+15,327
New +$642K 0.01% 1232
2024
Q3 		– Sell
-12,707
Closed -$440K – 2344
2024
Q2 		$440K Sell
12,707
-24,863
-66% -$728K 0.01% 1278
2024
Q1 		$1.09M Buy
37,570
+25,048
+200% +$682K 0.03% 782
2023
Q4 		$287K Sell
12,522
-13,332
-52% -$233K 0.01% 1478
2023
Q3 		$431K Buy
+25,854
New +$502K 0.02% 1131
2023
Q2 		– Sell
-9,278
Closed -$213K – 1964
2023
Q1 		$213K Sell
9,278
-5,910
-39% -$99.3K 0.01% 1401
2022
Q4 		$166K Buy
+15,188
New +$128K 0.01% 1420
2022
Q3 		– Sell
-11,383
Closed -$90K – 1990
2022
Q2 		$90K Sell
11,383
-45,380
-80% -$549K ﹤0.01% 1749
2022
Q1 		$1.34M Buy
+56,763
New +$1.6M 0.05% 496
2021
Q3 		– Sell
-4,710
Closed -$211K – 1912
2021
Q2 		$211K Buy
+4,710
New +$155K 0.01% 1377
2021
Q1 		– Sell
-13,030
Closed -$263K – 2068
2020
Q4 		$263K Buy
+13,030
New +$280K 0.01% 1376

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Engineers Gate Manager's PTGX Position: Q2 2025 in Review

Engineers Gate Manager sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 15,327 shares — an estimated $741K sold.

Engineers Gate Manager first reported a position in PTGX in Q4 2020 and held it in 11 quarters. The position peaked at $1.34M in Q1 2022. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Engineers Gate Manager reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Engineers Gate Manager sold 15,327 Protagonist Therapeutics shares in Q2 2025, an estimated $741K.
  • Engineers Gate Manager first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 11 quarters.
  • Engineers Gate Manager's Protagonist Therapeutics position peaked at $1.34M in Q1 2022.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Engineers Gate Manager's 13F filing for Q2 2025, filed 14 Aug 2025.